Resveratrol inhibits hepatic stellate cell activation by regulating autophagy and apoptosis through the SIRT1 and JNK signaling pathways

doi:10.21203/rs.3.rs-1650543/v1

Download PDF

Research Article

Resveratrol inhibits hepatic stellate cell activation by regulating autophagy and apoptosis through the SIRT1 and JNK signaling pathways

https://doi.org/10.21203/rs.3.rs-1650543/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Resveratrol, a natural polyphenol found in grapes, berries, peanuts, and medicinal plants, has previously been reported to have several biological activities, including inhibiting hepatic fibrosis. Hepatic stellate cell (HSC) activation is the major cellular source of matrix protein-secreting myofibroblasts, which are the major drivers of liver fibrogenesis. Numerous studies on the protective effects of resveratrol against liver fibrosis have focused on the inhibition of HSC activation. Although the underlying mechanisms remain to be fully elucidated, autophagy and apoptosis regulation might be intimately related. The mouse HSC line JS1 was stimulated with resveratrol to assess the mechanism and relationship between autophagy and apoptosis. Resveratrol dose-dependently modulated JS1 cell viability. Moreover, resveratrol inhibited JS1 cell activation and induced autophagy and apoptosis. This antifibrotic effect was attenuated when autophagy was inhibited using chloroquine (CQ) or 3-methyladenine (3-MA) or when apoptosis was inhibited using Z-VAD-FMK. Furthermore, whether the Sirtuin1 (SIRT1) and c-Jun N-terminal kinase (JNK) signaling pathways were associated with resveratrol-induced autophagy and apoptosis in JS1 cells was examined. The SIRT1 inhibitor EX527 reversed autophagy, and the JNK inhibitor SP600125 was able to reverse both autophagy and apoptosis induced by resveratrol. These findings suggest that the SIRT1 and JNK signaling pathways may be involved in resveratrol-mediated inhibition of HSC activation by regulating autophagy and apoptosis.

resveratrol

autophagy

apoptosis

hepatic stellate cells

SIRT1

JNK

Hepatic fibrosis is a dynamic process characterized by the net accumulation of extracellular matrix (ECM), which results from chronic liver injury of any etiology, including viral infection, alcoholic liver disease and nonalcoholic steatohepatitis [1]. Hepatic stellate cell (HSC) activation is the major cellular source of matrix protein-secreting myofibroblasts, which are the major drivers of liver fibrogenesis [2]. Therefore, inhibiting the proliferation and clearance of activated HSCs remains the major therapeutic strategy for liver fibrosis [3].

Resveratrol (3,4′,5-trihydroxy-trans-stilbene), a natural polyphenol found in grapes, berries, peanuts, and medicinal plants, has several biological activities, including anticarcinogenic, antiaging, antioxidant, anti-inflammatory, and lipid modulating activities [4, 5]. Moreover, numerous studies have shown that resveratrol has a dose-dependent effect and can exert opposite effects in a variety of diseases depending on the concentration, time of exposure, and cell type [6–8]. Recent reports have shown that resveratrol can prevent or slow the progression of various fibrotic diseases, including cardiac fibrosis [9], pulmonary fibrosis [10], renal fibrosis [11], prostate fibrosis [12] and systemic sclerosis [13]. In liver fibrosis, resveratrol provides significant protection against fibrosis induced by carbon tetrachloride (CCl₄) [14, 15], dimethylnitrosamine [16], bile duct ligation [17], and Schistosoma japonicum [18]. In fact, resveratrol reduces portal pressure, HSC activation, inflammatory cell infiltration of liver tissue, and fibrosis and improves hepatic endothelial function in cirrhotic rats [19]. Numerous in vitro studies on the effects of resveratrol against liver fibrosis focused on the inhibition of HSC activation. Although the underlying mechanisms remain to be fully elucidated, autophagy and apoptosis regulation might be intimately related.

Autophagy and apoptosis are functionally distinct mechanisms of cytoplasmic and cellular turnover [20]. Autophagy is an essential catabolic degradation process in which cellular proteins, organelles and invading microbes are engulfed by double-membraned autophagosomes and degraded in lysosomes [21]. Basal autophagy occurs in all types of cells; however, uncontrolled autophagy leads to programmed cell death [21]. Apoptosis is widely appreciated as a major mechanism of regulated death, which may be triggered by extrinsic stimuli through cell surface death receptors or by intrinsic stimuli via the mitochondrial signaling pathway. Caspase activation results in mitochondrial membrane permeabilization, chromatin condensation and DNA fragmentation, thereby leading to the destruction of the cell [22]. The two pathways are regulated by common factors, and each can regulate and modify the activity of the other. The crosstalk between autophagy and apoptosis is complex and determines cell death or survival and the progression of liver disease [23]. Recently, it has been reported that resveratrol could modulate autophagy [24] and apoptosis [15] as the main forms of HSC death through various signaling pathways.

The therapeutic effect of resveratrol on hepatic fibrosis and the possible roles of autophagy and apoptosis induction in this process are not yet clear. In the present study, we aimed to evaluate the inhibitory effect of resveratrol on HSC activation and focused on the mechanism by which resveratrol modulated autophagy and apoptosis in JS1 cells, a mouse immortalized HSC line.

Cells and cell culture

The immortalized mouse HSC line JS1 was kindly provided by Professor Scott L. Friedman (Mt. Sinai School of Medicine, USA). JS1 cells were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin at 5% CO₂ and 37°C. The medium was replaced with media supplemented with 0.5% FBS for 12 h prior to treatment. Different concentrations of resveratrol (cat. no. R5010; Sigma) was added to the medium and an incubated for different durations, according to the experimental design. JS1 cells were pretreated with 5 mM 3-methyladenine (3-MA; cat. no. M9281; Sigma–Aldrich; Merck KGaA), 30 µM chloroquine (CQ) diphosphate salt (cat. no. C6628; Sigma–Aldrich; Merck KGaA) or 20 µM Z-VAD-FMK (cat. no. C1202; Beyotime Institute of Biotechnology) for 2 h and 10 µM EX527 (cat. no. ab141506; Abcam) or 10 µM SP600125 (cat. no. ab120065; Abcam) for 1 h, followed by treatment with or without 50 µM resveratrol for 24 h. Each in vitro experiment was repeated three times.

Measurement of JS1 cell viability

Cells were plated in plastic 96-well plates and incubated with 0.1, 1, 10, 50 or 100 µM resveratrol for 24 h. Subsequently, cell viability was assessed using an MTT Cell Proliferation and Cytotoxicity Assay kit (cat. no. C0009; Beyotime Institute of Biotechnology) according to the manufacturer’s protocol. The supernatant was removed after the cells were treated, and 90 µl of fresh culture medium and 10 µl of MTT solution were added and incubated for 4 h at 37°C. The cell supernatant was then discarded, and 100 µl of formazan was added with gentle shaking for 10 min. The absorbance was recorded at a wavelength of 490 nm with a microplate reader (SpectraMax M5; Molecular Devices LLC).

Western blotting

JS1 cells were prepared for electrophoresis as previously described [25]. After being resolved, the protein concentration was measured using a bicinchoninic acid protein assay kit (cat. no. P0012; Beyotime Institute of Biotechnology). Proteins were separated by SDS–PAGE (5% stacking gel, 10 or 15% separating gel; 30 µg of protein in 15 µl of volume per lane) and subsequently transferred to a PVDF membrane. The membrane was blocked in blocking buffer (cat. no. 927-40000; LI-COR Biosciences) for 1 h at room temperature and incubated with primary antibodies overnight at 4°C. Subsequently, the membrane was incubated with a fluorescently tagged secondary antibody in the dark at room temperature for 45 min and measured at a wavelength of 800 nm (780 nm excitation, 820 nm detection) or 700 nm (680 nm excitation, 720 nm detection) with an Odyssey Infrared Imaging System (Odyssey; LI-COR Biosciences) according to the manufacturer’s instructions. ImageJ 6.0 (National Institutes of Health) was used for quantification. The following antibodies were used: rabbit anti-collagen type I (Col. I; cat. no. ab292; Abcam), rabbit anti-microtubule-associated protein 1 light chain 3B (LC3B; cat. no. L7543; Sigma–Aldrich; Merck KGaA), rabbit anti-p62 (cat. no. 5114; Cell Signaling Technology, Inc.), rabbit anti-cleaved caspase3 (cat. no. 9664; Cell Signaling Technology, Inc.), rabbit anti-c-Jun N-terminal kinase (JNK) (cat. no. 9258; Cell Signaling Technology, Inc.), rabbit anti-phosphorylated (p)-JNK (cat. no. 4671; Cell Signaling Technology, Inc.), rabbit anti-Sirtuin1 (SIRT1) (cat. no. sc-15404, Santa Cruz) (all diluted 1:500) and mouse anti-GAPDH (cat. no. KC-5G4; 1:10,000; KangChen BioTech Co., Ltd.). The secondary antibodies used were as follows: IRDye 680RD goat anti-rabbit (cat. no. 926-68071; LI-COR Biosciences) and IRDye 800CW donkey anti-mouse (cat. no. 926-32212; LI-COR Biosciences) (1:10,000 dilution).

Reverse transcription-quantitative polymerase chain reaction (RT–qPCR)

RT–qPCR was performed as previously described to determine the gene expression levels in the cultured cells [26]. Total RNA was extracted from the cells using a nucleic acid purification kit (cat. no. NPK-201; Toyobo Life Science), and cDNA was synthesized using a RevertAid First Strand cDNA Synthesis kit (cat. no. K1622; Thermo Fisher Scientific, Inc.) according to the manufacturer’s instructions. Total cDNA was mixed with PCR master mix (cat. no. DRR041A; Takara Bio, Inc.) and predesigned primers. The following primer pairs (synthesized by Sangon Biotech Co., Ltd.) were used for qPCR: Atg7 forward, 5’-GGAGAAGAACCAGAAAGGAGGC-3’ and reverse, 5’-GCAGGCACTTGACAGACACGAC-3’; Beclin1 forward, 5’-CTTACCACAGCCCAGGCGAA-3’ and reverse, 5’-AGATGCCTCCCCGATCAGAG-3’; Bcl-2 forward, 5’-TGTGGAGAGCGTCAACAGGG-3’ and reverse, 5’-AGACAGCCAGGAGAAATCAAACAGA-3’; and GAPDH forward, 5’-AAGGTCATCCATGACAACTTTGGC-3’ and reverse, 5’-ACAGTCTTCTGGGTGGCAGTGAT-3’. GAPDH was used as the internal reference gene. The thermocycling conditions used for qPCR were as follows: initial denaturation for 1 min at 95°C, followed by 40 cycles of 15 sec at 95°C and 30 sec at 60°C. Amplification was performed on a ViiA7 system (Thermo Fisher Scientific, Inc.). Gene expression was normalized to that of GAPDH using the 2^− ΔΔCq method [27].

Statistical analysis

Data were collected in triplicate from at least three separate cell cultures. The results are expressed as the mean ± SEM of three repeats. Differences among groups were compared using one-way ANOVA followed by Tukey’s post-hoc test or a t test. SPSS 17.0 (SPSS, Inc.) was used to perform statistical analyses. P < 0.05 was considered to indicate a statistically significant difference.

Resveratrol inhibits JS1 cell activation

Resveratrol is well known to exert cytotoxic effects by inducing death in various cell types. JS1 cells were used in our study, and we examined the effect of various concentrations of resveratrol on JS1 cells. As shown in Fig. 1a, proliferation was significantly reduced after 24 h of treatment with higher doses (50, 100 µM) of resveratrol. Conversely, lower doses (0.1, 1, 10 µM) slightly promoted cell proliferation. These findings indicated that resveratrol dose-dependently affected the viability of JS1 cells and even exerted opposing effects at different doses.

Moreover, we observed that higher doses (50, 100 µM) of resveratrol significantly inhibited the protein and mRNA expression of Col. I in JS1 cells compared with controls (Fig. 1b-d), and these results were consistent with previous studies showing that higher doses of resveratrol inhibited cell viability. However, these results were inconsistent when the concentration was 10 µM. As shown in Fig. 1b and c, 10 µM resveratrol significantly inhibited the protein expression of Col. I but had no effect on Col. I mRNA, which may be attributed to resveratrol promoting the degradation of intracellular Col. Taken together, these findings were consistent with those of previous reports [6, 28, 29], showing that resveratrol had a dose-dependent effect on HSC viability and inhibited HSC activation at higher doses.

Resveratrol inhibits HSC activation by inducing autophagy and apoptosis

Studies have shown that resveratrol-induced autophagy or apoptosis regulates fibrosis in multiple types of fibroblasts, including fibroblast-like synovial cells [30], primary mouse embryonic fibroblasts [31], human dermal fibroblasts [32], keloid fibroblasts [33] and rat cardiac fibroblasts [8]. We sought to determine whether resveratrol also induced autophagy and apoptosis in JS1 cells. As shown in Fig. 2a, the expression of the autophagy marker LC3BII was significantly increased in JS1 cells treated with lower doses (0.1, 1, 10 µM) of resveratrol for 12 h. Moreover, the expression of the apoptotic marker cleaved caspase3 was increased in response to higher doses (50, 100 µM) of resveratrol. Interestingly, higher and lower concentrations induced the opposite effects on LC3BⅡ and cleaved caspase3. Subsequently, whether there was an association between autophagy and apoptosis in HSCs was assessed.

JS1 cells were treated with 50 and 10 µM resveratrol for 4 and 12 h, which decreased in Col. I expression (Fig. 2b). Furthermore, we observed that compared with the control, 50 µM resveratrol significantly increased LC3BII and inhibited p62 expression at 4 h and increased cleaved caspase 3 expression after 8 h. Resveratrol (10 µM) significantly increased LC3BII and inhibited p62 expression at 12 h and increased cleaved caspase 3 expression at 24 h. These results suggested that resveratrol induced autophagy and apoptosis successively at different times, autophagy preceded apoptosis, and the effect of initiating autophagy and apoptosis was postponed by decreasing the resveratrol concentration.

In addition, JS1 cells were treated with 50 µM resveratrol for 4 and 24 h, and the PCR results are shown in Fig. 2c. Compared with those in the controls, the mRNA expression levels of autophagy-related genes (Atg7, Beclin1) and an antiapoptotic gene (Bcl-2) were significantly upregulated at 4 h and downregulated at 24 h. Taken together, these results suggested that resveratrol induced autophagy prior to apoptosis in JS1 cells. Autophagy is upstream of apoptosis because autophagy may be an adaptive stress response prior to apoptotic cell death [23].

It was hypothesized that resveratrol inhibits HSC activation by inducing autophagy and apoptosis. Therefore, blocking autophagy or apoptosis may attenuate the antifibrotic effects of resveratrol. JS1 cell were stimulated with 50 µM resveratrol in the presence of autophagy or apoptosis inhibitors, and the effects were assessed. The results suggested that treatment with 3-MA, CQ (pharmacological inhibitors of autophagy) or Z-VAD-FMK (pancaspase inhibitor) significantly attenuated the inhibitory effect of resveratrol on Col. I expression (Fig. 2d). Therefore, inhibiting autophagy or apoptosis may reduce resveratrol-mediated inhibition of JS1 cell activation, suggesting that the induction of autophagy and apoptosis might be required for resveratrol-mediated inhibition of hepatic fibrosis.

Resveratrol regulates autophagy and apoptosis by activating the SIRT1 and JNK signaling pathways

The mechanisms involved in autophagy and apoptosis were next investigated. SIRT1 is a member of the class III histone deacetylase family that is distinctively dependent on nicotinamide adenine dinucleotide (NAD+) for catalytic reactions [34]; SIRT1 modulates gene expression, apoptosis, energy homeostasis, autophagy, acute stress responses, and mitochondrial biogenesis [35]. As resveratrol is an agonist of SIRT1, the activation of SIRT1 signaling is considered a key mechanism for its effects on a variety of diseases [36–38]. Additionally, studies have also shown that the JNK pathway is a potential target of resveratrol [39, 40]. JNKs are among the most crucial mitogen-activated protein kinases (MAPKs), which have been shown to play roles in apoptotic and nonapoptotic programmed cell death, including necroptosis, ferroptosis, pyroptosis, and autophagy [41]. Thus, it was hypothesized that the SIRT1 and JNK signaling pathways may be involved in resveratrol-induced autophagy and apoptosis in JS1 cells.

JS1 cell were stimulated with resveratrol in the presence of the SIRT1 inhibitor EX527 and JNK inhibitor SP600125, and the effects were assessed to investigate the role of resveratrol-induced autophagy and apoptosis. Subsequently, the expression of Col. I, LC3BII and cleaved caspase3 were examined by western blotting. As shown in Fig. 3a, resveratrol treatment resulted in a significant decrease in the expression of the fibrosis marker Col. I, and the effect was partially reversed by treatment with the SIRT1 inhibitor EX527. Moreover, EX527 abrogated SIRT1 and LC3BII expression in the presence of resveratrol at 24 h. However, the expression of cleaved caspase3 induced by resveratrol was increased by EX527. This finding suggested that resveratrol may partly induce autophagy to inhibit HSC activation via the SIRT1 pathway.

As shown in Fig. 3b, the JNK inhibitor SP600125 reversed JNK phosphorylation and significantly decreased the expression of Col. I, LC3BII and cleaved caspase3 in the presence of resveratrol. Resveratrol-induced autophagy and apoptosis were reduced by inhibition of the JNK signaling pathway. In conclusion, these findings suggest that SIRT1 may induce autophagy, while JNK affects both autophagy and apoptosis during resveratrol-mediated inhibition of HSC activation.

In the present study, it was shown that resveratrol induced both autophagy and apoptosis while inhibiting HSC activation. Furthermore, inhibiting autophagy with CQ and 3-MA or inhibiting apoptosis with Z-VAD-FMK reversed the antifibrotic effects of resveratrol. These results showed that resveratrol inhibited HSC activation by inducing autophagy and apoptosis in a dose-dependent manner, and the mechanism may be associated with the SIRT1 and JNK signaling pathways.

A large amount of evidence suggests that resveratrol exerts dose-dependent effects and even contradictory effects on various cell types or diseases. For example, in renal fibrosis, Liu et al. [11] showed that resveratrol activated antifibrotic or profibrotic effects on kidneys depending on the dose. In vivo, low-dose treatment with resveratrol (≤ 25 mg/kg) partly improved renal function, whereas high-dose treatment with resveratrol (≥ 50 mg/kg) had no antifibrotic effect and even exacerbated renal fibrosis. In addition, resveratrol at concentrations greater than 25–50 µM typically trigger growth arrest, senescence and/or apoptosis in different cell types. In contrast, concentrations less than 10 µM enhance the growth of log phase cell cultures and can rescue senescence in multiple types of human fibroblasts [42].

There are also conflicting reports on HSC activation due to different concentrations of resveratrol. Resveratrol (15 µM) upregulated the mRNA expression of α-smooth muscle actin (α-SMA) and amplified the profibrogenic effects of free fatty acids on LX-2 cells (human HSC line) [43]. In contrast, resveratrol decreased t-HSC/Cl-6 cell (rat HSC line) viability at very low concentrations (1.56 µM) at 24 h [28]. de Oliveira et al. [29] suggested that resveratrol at 1 and 10 µM did not alter the protein levels of α-SMA, collagen I and glial fibrillary acidic protein (GFAP) in GRX cells (mouse HSC line). Resveratrol at 10 and 50 µM decreased GRX cell migration and collagen I contraction. Consistent with previous studies, the results of the present study showed that resveratrol exerted dose-dependently supported or inhibited JS1 cell proliferation (Fig. 1a). Furthermore, the effect of resveratrol on HSC was not only dose-dependent but also time-dependent. Martins et al. [6] reported that treating GRX cells with 50 µM resveratrol for 24 h induced oxidative stress-related damage, drastically reducing cell viability, but this cytotoxicity seemed to be attenuated after 120 h. The complex effects of resveratrol on promoting or preventing HSC activation may be dependent on different cell types, concentrations, and durations of treatment.

In the present study, resveratrol inhibited the mRNA and protein expression of Col. I. However, the results were inconsistent when JS1 cells were treated with 10 µM resveratrol. As shown in Figs. 1a-c and 2a, 10 µM resveratrol promoted cell viability, increased LC3BII expression and significantly inhibited Col. I protein expression but had no effect on Col. I mRNA expression. Therefore, we concluded that resveratrol promoted intracellular Col. I degradation through autophagy rather than inhibiting its production in JS1 cells. Autophagy is an important protein degradation pathway. A large amount of research has shown that Col. I, which is the major component of the ECM, is degraded by the autophagy–lysosome system [44, 45]. For example, Kawano et al. [45] showed that internalized collagen accumulated in autophagy-deficient murine embryonic fibroblasts. Kim et al. [46] reduced Beclin1 expression through genetic disruption of Beclin1 or knockdown with specific siRNA in primary mouse mesangial cells and showed that this resulted in increased protein levels of Col. I. Moreover, autophagy exerts antifibrotic effects and enhances collagen degradation in intestinal fibroblasts [47], cardiac fibroblasts [48], and lung fibroblasts [49]. However, other studies reported contrasting results. Nakamura et al. [50] showed that autophagy facilitated type I collagen synthesis in periodontal ligament cells. Additionally, inhibiting autophagy promoted collagen degradation in pancreatic stellate cells [51]. The complex role of autophagy in promoting or inhibiting collagen degradation may be dependent on different cell types.

Autophagy and apoptosis are well-controlled biological processes that determine the cell death or survival and the development of diseases. Accumulating evidence reveals that autophagy and apoptosis can cooperate, antagonize, or assist each other, and the crosstalk between these processes is complex [22]. As shown in Fig. 2b, both high and low concentrations of resveratrol induced autophagy and apoptosis successively at different times. The autophagic response occurs earlier than apoptotic cell death, placing autophagy upstream of apoptosis. Autophagy may be an adaptive stress response prior to apoptotic cell death. Furthermore, autophagy can induce or antagonize apoptosis [23]. Autophagy antagonizes apoptosis and promotes cell survival via a series of responses to damaged organelles, endoplasmic reticulum stress, DNA stability, or loss of nutrient and growth factor signaling pathways. Conversely, autophagic activation beyond a certain threshold may result in the collapse of cellular function, directly resulting in autophagic cell death or the execution of apoptotic cell death via common regulators [23]. In conclusion, resveratrol induced autophagy and apoptosis in JS1 cells, and crosstalk may occur between these processes. Resveratrol increased autophagic flux and may directly induce autophagic cell death, while the overactivation of autophagy contributes to apoptotic cell death.

As previously reported, the SIRT1 signaling pathway is involved in the regulation of autophagy and apoptosis and has been studied as part of the mechanism of resveratrol in various diseases [36–38]. Previous studies have shown that SIRT1 increases autophagic flux, and this effect may be mediated by the class III PI3K/Beclin1 and mTOR signaling pathways [34, 52, 53]. Moreover, p53 deacetylation by SIRT1 has been confirmed to play a significant role in inhibiting apoptosis [54]. As shown in Fig. 3a, our findings suggested that SIRT1 signaling induced autophagy to participate in the antifibrotic effects of resveratrol, which were probably attributable to autophagy-mediated promotion of Col. I degradation in HSCs. In addition, we observed that the SIRT1 inhibitor EX527 upregulated the expression of cleaved caspase3 induced by resveratrol in JS1 cells (Fig. 3a). That is, resveratrol inhibited apoptosis by inducing autophagy through the SIRT1 signaling pathway, which may be attributed to autophagy antagonizing apoptosis. Autophagy may partially counteract apoptotic cell death via the cell survival pathway at an earlier stage. Similar results were recently reported in which resveratrol induced SIRT1-dependent autophagy to prevent apoptosis in VSC4.1 motoneurons [55], intestinal epithelial cells [56] and human trophoblasts [57].

JNK signaling may play critical roles in many biological diseases by regulating various cellular processes, including inflammatory responses, differentiation, proliferation, death, and survival [58]. JNKs are among the most crucial MAPKs and include JNK1, JNK2, and JNK3. All three JNKs have been shown to be involved in stimulating apoptotic signaling [41]. A general mechanism through which JNKs modulate the apoptotic pathway involves stimulating the expression of proapoptotic genes and decreasing the expression of prosurvival genes via multiple transcription factors. In addition to their effect on gene expression, JNKs actively regulate both the intrinsic and extrinsic apoptotic pathways [41]. Furthermore, the JNK signaling pathway has also been reported to participate in autophagy regulation in response to various stress signals. JNK induces autophagic cell death by enhancing the expression of autophagy-related genes, including Atg5, Atg7, LC3, and Beclin1 [41]. In the present study, the role of the JNK pathway in resveratrol-induced autophagy and apoptosis was assessed. We observed that the JNK inhibitor SP600125 could attenuate autophagy and apoptosis in JS1 cells induced by resveratrol. Resveratrol exerted antifibrotic effects by mediating the JNK pathway and inducing apoptosis and autophagy in HSCs. A similar result was reported in cardiac cells. Xu et al. [59] reported that resveratrol protected cardiac cells by regulating the switch between autophagy and apoptotic machinery under diabetic conditions, and this effect was associated with JNK-mediated Beclin1-Bcl-2 dissociation. Bcl-2 is an important mediator of JNK-mediated autophagy and apoptosis activation. Activated JNK phosphorylates Bcl-2/Bcl-xL to release Beclin1 from the Beclin1-Bcl-2/Bcl-xL complex and promote autophagy. Sustained Bcl-2 phosphorylation not only leads to Beclin1-mediated autophagic cell death but also antagonizes the antiapoptotic activity of Bcl-2/Bcl-xL via a Bid-Bax-dependent mechanism [58, 60, 61].

In conclusion, the present study showed that resveratrol inhibited HSC activation by regulating autophagy and apoptosis by activating the SIRT1 and JNK signaling pathways. SIRT1 may be responsible for inducing autophagy, while JNK affects both autophagy and apoptosis. This study highlighted autophagy and apoptosis as therapeutic targets by which resveratrol can attenuate fibrosis. Additionally, these findings may provide a new framework for understanding the mechanism by which resveratrol inhibits HSC activation. However, autophagy and apoptosis may act independently on the SIRT1 and JNK pathways or may influence one another, which requires further study.

Acknowledgments

We would like to thank Professor Scott L. Friedman (Icahn School of Medicine at Mount Sinai, USA) for providing the immortalized mouse HSC line JS1.

Funding

This study was supported by the General Program of the National Natural Science Foundation of China (No. 81373859), the Youth Program of Shanghai Municipal Health Commission (No. 20204Y0046) and the Traditional Chinese Medicine Project of Shanghai Jiading District Health Commission (No. 2018-QN-ZYY-01).

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

Author contributions

Lieming Xu conceived and designed the study and contributed reagents and materials. Jing Zhang, Jian Ping and Na Jiang performed the research and analyzed the data. Jing Zhang wrote the manuscript and prepared Figs. 1-3. Jian Ping analyzed and interpreted the data and revised the manuscript. All authors reviewed and approved the final manuscript.

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Not applicable.

Consent to publish

Not applicable.

Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14:397–411. https://doi.org/10.1038/nrgastro.2017.38
Higashi T, Friedman SL, Hoshida Y (2017) Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev 121:27–42. https://doi.org/10.1016/j.addr.2017.05.007
Meira Martins LA, Vieira MQ, Ilha M, de Vasconcelos M, Biehl HB, Lima DB, Schein V, Barbe-Tuana F, Borojevic R, Guma FC (2015) The interplay between apoptosis, mitophagy and mitochondrial biogenesis induced by resveratrol can determine activated hepatic stellate cells death or survival. Cell Biochem Biophys 71:657–672. https://doi.org/10.1007/s12013-014-0245-5
Chupradit S, Bokov D, Zamanian MY, Heidari M, Hakimizadeh E (2021) Hepatoprotective and therapeutic effects of resveratrol: a focus on anti-inflammatory and antioxidative activities. Fundam Clin Pharmacol. https://doi.org/10.1111/fcp.12746
Ahmadi A, Hayes AW, Karimi G (2021) Resveratrol and endoplasmic reticulum stress: a review of the potential protective mechanisms of the polyphenol. Phytother Res 35:5564–5583. https://doi.org/10.1002/ptr.7192
Martins LA, Coelho BP, Behr G, Pettenuzzo LF, Souza IC, Moreira JC, Borojevic R, Gottfried C, Guma FC (2014) Resveratrol induces pro-oxidant effects and time-dependent resistance to cytotoxicity in activated hepatic stellate cells. Cell Biochem Biophys 68:247–257. https://doi.org/10.1007/s12013-013-9703-8
Lee CH, Kim KW, Lee SM, Kim SY (2020) Dose-dependent effects of resveratrol on cisplatin-induced hearing loss. Int J Mol Sci 22:113. https://doi.org/10.3390/ijms22010113
Lieben Louis X, Meikle Z, Chan L, DeGagne G, Cummer R, Meikle S, Krishnan S, Yu L, Netticadan T, Wigle JT (2019) Divergent effects of resveratrol on rat cardiac fibroblasts and cardiomyocytes. Molecules 24:2604. https://doi.org/10.3390/molecules24142604
Zivarpour P, Reiner Ž, Hallajzadeh J, Mirsafaei L (2022) Resveratrol and cardiac fibrosis prevention and treatment. Curr Pharm Biotechnol 23:190–200. https://doi.org/10.2174/1389201022666210212125003
Wang Z, Li X, Chen H, Han L, Ji X, Wang Q, Wei L, Miu Y, Wang J, Mao J, Zhang Z (2021) Resveratrol alleviates bleomycin-induced pulmonary fibrosis via suppressing HIF-1α and NF-κB expression. Aging (Albany NY) 13:4605–4616. https://doi.org/10.18632/aging.202420
Liu S, Zhao M, Zhou Y, Wang C, Yuan Y, Li L, Bresette W, Chen Y, Cheng J, Lu Y, Liu J (2019) Resveratrol exerts dose-dependent anti-fibrotic or pro-fibrotic effects in kidneys: a potential risk to individuals with impaired kidney function. Phytomedicine 57:223–235. https://doi.org/10.1016/j.phymed.2018.12.024
Vicari E, Arancio A, Catania VE, Vicari BO, Sidoti G, Castiglione R, Malaguarnera M (2020) Resveratrol reduces inflammation-related prostate fibrosis. Int J Med Sci 17:1864–1870. https://doi.org/10.7150/ijms.44443
Yao Q, Wu Q, Xu X, Xing Y, Liang J, Lin Q, Huang M, Chen Y, Lin B, Chen W (2020) Resveratrol ameliorates systemic sclerosis via suppression of fibrosis and inflammation through activation of SIRT1/mTOR signaling. Drug Des Devel Ther 14:5337–5348. https://doi.org/10.2147/dddt.S281209
Ma Z, Sheng L, Li J, Qian J, Wu G, Wang Z, Zhang Y (2022) Resveratrol alleviates hepatic fibrosis in associated with decreased endoplasmic reticulum stress-mediated apoptosis and inflammation. Inflammation 45:812–823. https://doi.org/10.1007/s10753-021-01586-w
Li C, Zhang R, Zhan Y, Zheng J (2021) Resveratrol inhibits hepatic stellate cell activation via the hippo pathway. Mediators Inflamm 2021:3399357. https://doi.org/10.1155/2021/3399357
Abdu SB, Al-Bogami FM (2019) Influence of resveratrol on liver fibrosis induced by dimethylnitrosamine in male rats. Saudi J Biol Sci 26:201–209. https://doi.org/10.1016/j.sjbs.2017.09.003
ShamsEldeen AM, Al-Ani B, Ebrahim HA, Rashed L, Badr AM, Attia A, Farag AM, Kamar SS, Haidara MA, Al Humayed S, Ali Eshra M (2021) Resveratrol suppresses cholestasis-induced liver injury and fibrosis in rats associated with the inhibition of TGFβ1-Smad3-miR21 axis and profibrogenic and hepatic injury biomarkers. Clin Exp Pharmacol Physiol 48:1402–1411. https://doi.org/10.1111/1440-1681.13546
Chen TT, Peng S, Wang Y, Hu Y, Shen Y, Xu Y, Yin J, Liu C, Cao J (2019) Improvement of mitochondrial activity and fibrosis by resveratrol treatment in mice with Schistosoma japonicum infection. Biomolecules 9:658. https://doi.org/10.3390/biom9110658
Izzo C, Annunziata M, Melara G, Sciorio R, Dallio M, Masarone M, Federico A, Persico M (2021) The role of resveratrol in liver disease: a comprehensive review from in vitro to clinical trials. Nutrients 13:933. https://doi.org/10.3390/nu13030933
Bata N, Cosford NDP (2021) Cell survival and cell death at the intersection of autophagy and apoptosis: implications for current and future cancer therapeutics. ACS Pharmacol Transl Sci 4:1728–1746. https://doi.org/10.1021/acsptsci.1c00130
Mizushima N, Levine B, Cuervo AM, Klionsky DJ (2008) Autophagy fights disease through cellular self-digestion. Nature 451:1069–1075. https://doi.org/10.1038/nature06639
Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N (2013) Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta 1833:3448–3459. https://doi.org/10.1016/j.bbamcr.2013.06.001
Wang K (2015) Autophagy and apoptosis in liver injury. Cell Cycle 14:1631–1642. https://doi.org/10.1080/15384101.2015.1038685
Zhu L, Mou Q, Wang Y, Zhu Z, Cheng M (2020) Resveratrol contributes to the inhibition of liver fibrosis by inducing autophagy via the microRNA20amediated activation of the PTEN/PI3K/AKT signaling pathway. Int J Mol Med 46:2035–2046. https://doi.org/10.3892/ijmm.2020.4748
Lv Z, Song Y, Xue D, Zhang W, Cheng Y, Xu L (2010) Effect of salvianolic-acid B on inhibiting MAPK signaling induced by transforming growth factor-beta1 in activated rat hepatic stellate cells. J Ethnopharmacol 132:384–392. https://doi.org/10.1016/j.jep.2010.05.026
Liu CH, Hu YY, Wang XL, Liu P, Xu LM (2000) Effects of salvianolic acid-A on NIH/3T3 fibroblast proliferation, collagen synthesis and gene expression. World J Gastroenterol 6:361–364. https://doi.org/10.3748/wjg.v6.i3.361
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408. https://doi.org/10.1006/meth.2001.1262
Zhang DQ, Sun P, Jin Q, Li X, Zhang Y, Zhang YJ, Wu YL, Nan JX, Lian LH (2016) Resveratrol regulates activated hepatic stellate cells by modulating NF-kappaB and the PI3K/Akt signaling pathway. J Food Sci 81:H240-H245. https://doi.org/10.1111/1750-3841.13157
de Oliveira CM, Martins LAM, de Sousa AC, Moraes KDS, Costa BP, Vieira MQ, Coelho BP, Borojevic R, de Oliveira JR, Guma FCR (2021) Resveratrol increases the activation markers and changes the release of inflammatory cytokines of hepatic stellate cells. Mol Cell Biochem 476:649–661. https://doi.org/10.1007/s11010-020-03933-1
Cao W, Zhang J, Wang G, Lu J, Wang T, Chen X (2018) Reducing-autophagy derived mitochondrial dysfunction during resveratrol promotes fibroblast-like synovial cell apoptosis. Anat Rec (Hoboken) 301:1179–1188. https://doi.org/10.1002/ar.23798
Ulakcsai Z, Bagaméry F, Szökő É, Tábi T (2018) The role of autophagy induction in the mechanism of cytoprotective effect of resveratrol. Eur J Pharm Sci 123:135–142. https://doi.org/10.1016/j.ejps.2018.07.039
Choi MS, Kim Y, Jung JY, Yang SH, Lee TR, Shin DW (2013) Resveratrol induces autophagy through death-associated protein kinase 1 (DAPK1) in human dermal fibroblasts under normal culture conditions. Exp Dermatol 22:491–494. https://doi.org/10.1111/exd.12175
Si L, Zhang M, Guan E et al (2020) Resveratrol inhibits proliferation and promotes apoptosis of keloid fibroblasts by targeting HIF-1α. J Plast Surg Hand Surg 54:290–296. https://doi.org/10.1080/2000656x.2020.1771719
Yousafzai NA, Jin H, Ullah M, Wang X (2021) Recent advances of SIRT1 and implications in chemotherapeutics resistance in cancer. Am J Cancer Res 11:5233–5248
Tovar-Palacio C, Noriega LG, Mercado A (2022) Potential of polyphenols to restore SIRT1 and NAD + metabolism in renal disease. Nutrients 14:653. https://doi.org/10.3390/nu14030653
Chen Q, Zeng Y, Yang X, Wu Y, Zhang S, Huang S, Zhong Y, Chen M (2022) Resveratrol ameliorates myocardial fibrosis by regulating Sirt1/Smad3 deacetylation pathway in rat model with dilated cardiomyopathy. BMC Cardiovasc Disord 22:17. https://doi.org/10.1186/s12872-021-02401-y
Gomes BAQ, Silva JPB, Romeiro CFR, Dos Santos SM, Rodrigues CA, Gonçalves PR, Sakai JT, Mendes PFS, Varela ELP, Monteiro MC (2018) Neuroprotective mechanisms of resveratrol in Alzheimer's disease: role of SIRT1. Oxid Med Cell Longev 2018:8152373. https://doi.org/10.1155/2018/8152373
Nishigaki A, Tsubokura H, Tsuzuki-Nakao T, Okada H (2022) Hypoxia: role of SIRT1 and the protective effect of resveratrol in ovarian function. Reprod Med Biol 21:e12428. https://doi.org/10.1002/rmb2.12428
Wang J, He F, Chen L, Li Q, Jin S, Zheng H, Lin J, Zhang H, Ma S, Mei J, Yu J (2018) Resveratrol inhibits pulmonary fibrosis by regulating miR-21 through MAPK/AP-1 pathways. Biomed Pharmacother 105:37–44. https://doi.org/10.1016/j.biopha.2018.05.104
Shati AA (2019) Resveratrol improves sperm parameter and testicular apoptosis in cisplatin-treated rats: effects on ERK1/2, JNK, and Akt pathways. Syst Biol Reprod Med 65:236–249. https://doi.org/10.1080/19396368.2018.1541114
Dhanasekaran DN, Reddy EP (2017) JNK-signaling: a multiplexing hub in programmed cell death. Genes Cancer 8:682–694. https://doi.org/10.18632/genesandcancer.155
Birar VC, Sheerin AN, Ostler EL, Faragher RGA (2020) Novel resveratrol derivatives have diverse effects on the survival, proliferation and senescence of primary human fibroblasts. Biogerontology 21:817–826. https://doi.org/10.1007/s10522-020-09896-6
Bechmann LP, Zahn D, Gieseler RK, Fingas CD, Marquitan G, Jochum C, Gerken G, Friedman SL, Canbay A (2009) Resveratrol amplifies profibrogenic effects of free fatty acids on human hepatic stellate cells. Hepatol Res 39:601–608. https://doi.org/10.1111/j.1872-034X.2008.00485.x
Ishida Y, Yamamoto A, Kitamura A, Lamande SR, Yoshimori T, Bateman JF, Kubota H, Nagata K (2009) Autophagic elimination of misfolded procollagen aggregates in the endoplasmic reticulum as a means of cell protection. Mol Biol Cell 20:2744–2754. https://doi.org/10.1091/mbc.E08-11-1092
Kawano S, Torisu T, Esaki M, Torisu K, Matsuno Y, Kitazono T (2017) Autophagy promotes degradation of internalized collagen and regulates distribution of focal adhesions to suppress cell adhesion. Biol Open 6:1644–1653. https://doi.org/10.1242/bio.027458
Kim SI, Na HJ, Ding Y, Wang Z, Lee SJ, Choi ME (2012) Autophagy promotes intracellular degradation of type I collagen induced by transforming growth factor (TGF)-β1. J Biol Chem 287:11677–11688. https://doi.org/10.1074/jbc.M111.308460
Cosin-Roger J, Canet F, Macias-Ceja DC, Gisbert-Ferrandiz L, Ortiz-Masia D, Esplugues JV, Alos R, Navarro F, Barrachina MD, Calatayud S (2019) Autophagy stimulation as a potential strategy against intestinal fibrosis. Cells 8:1078. https://doi.org/10.3390/cells8091078
Liu S, Chen S, Li M, Zhang B, Shen P, Liu P, Zheng D, Chen Y, Jiang J (2016) Autophagy activation attenuates angiotensin II-induced cardiac fibrosis. Arch Biochem Biophys 590:37–47. https://doi.org/10.1016/j.abb.2015.11.001
Ghavami S, Yeganeh B, Zeki AA et al (2018) Autophagy and the unfolded protein response promote profibrotic effects of TGF-β(1) in human lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 314:L493-L504. https://doi.org/10.1152/ajplung.00372.2017
Nakamura T, Yamashita M, Ikegami K, Suzuki M, Yanagita M, Kitagaki J, Kitamura M, Murakami S (2021) Autophagy facilitates type I collagen synthesis in periodontal ligament cells. Sci Rep 11:1291. https://doi.org/10.1038/s41598-020-80275-4
Li CX, Cui LH, Zhuo YZ, Hu JG, Cui NQ, Zhang SK (2018) Inhibiting autophagy promotes collagen degradation by regulating matrix metalloproteinases in pancreatic stellate cells. Life Sci 208:276–283. https://doi.org/10.1016/j.lfs.2018.07.049
Yang X, Jiang T, Wang Y, Guo L (2019) The role and mechanism of SIRT1 in resveratrol-regulated osteoblast autophagy in osteoporosis rats. Sci Rep 9:18424. https://doi.org/10.1038/s41598-019-44766-3
Ghosh HS, McBurney M, Robbins PD (2010) SIRT1 negatively regulates the mammalian target of rapamycin. PLoS One 5:e9199. https://doi.org/10.1371/journal.pone.0009199
Zhang C, Feng Y, Qu S, Wei X, Zhu H, Luo Q, Liu M, Chen G, Xiao X (2011) Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res 90:538–545. https://doi.org/10.1093/cvr/cvr022
Tian H, Zhao H, Mei X, Li D, Lin J, Lin S, Song C (2021) Resveratrol inhibits LPS-induced apoptosis in VSC4.1 motoneurons through enhancing SIRT1-mediated autophagy. Iran J Basic Med Sci 24:38–43. https://doi.org/10.22038/ijbms.2020.44534.10416
Qin H, Zhang H, Zhang X, Zhang S, Zhu S, Wang H (2021) Resveratrol protects intestinal epithelial cells against radiation-induced damage by promoting autophagy and inhibiting apoptosis through SIRT1 activation. J Radiat Res 62:574–581. https://doi.org/10.1093/jrr/rrab035
Wang P, Huang CX, Gao JJ, Shi Y, Li H, Yan H, Yan SJ, Zhang Z (2020) Resveratrol induces SIRT1-dependent autophagy to prevent H(2)O(2)-induced oxidative stress and apoptosis in HTR8/SVneo cells. Placenta 91:11–18. https://doi.org/10.1016/j.placenta.2020.01.002
Chen J, Ye C, Wan C, Li G, Peng L, Peng Y, Fang R (2021) The roles of c-Jun N-Terminal Kinase (JNK) in infectious diseases. Int J Mol Sci 22:9640. https://doi.org/10.3390/ijms22179640
Xu K, Liu XF, Ke ZQ, Yao Q, Guo S, Liu C (2018) Resveratrol modulates apoptosis and autophagy induced by high glucose and palmitate in cardiac cells. Cell Physiol Biochem 46:2031–2040. https://doi.org/10.1159/000489442
Wu Q, Wu W, Fu B, Shi L, Wang X, Kuca K (2019) JNK signaling in cancer cell survival. Med Res Rev 39:2082–2104. https://doi.org/10.1002/med.21574
Fan YJ, Zong WX (2013) The cellular decision between apoptosis and autophagy. Chin J Cancer 32:121–129. https://doi.org/10.5732/cjc.012.10106

No competing interests reported.

Download PDF

Version 1

posted

You are reading this latest preprint version

Resveratrol inhibits hepatic stellate cell activation by regulating autophagy and apoptosis through the SIRT1 and JNK signaling pathways

Status:

Version 1

Abstract

Figures

Introduction

Materials And Methods

Cells and cell culture

Measurement of JS1 cell viability

Western blotting

Reverse transcription-quantitative polymerase chain reaction (RT–qPCR)

Statistical analysis

Results

Resveratrol inhibits JS1 cell activation

Resveratrol inhibits HSC activation by inducing autophagy and apoptosis

Resveratrol regulates autophagy and apoptosis by activating the SIRT1 and JNK signaling pathways

Discussion

Declarations

References

Additional Declarations

Status:

Version 1